On the other hand, gefitinib has been reported to be a radiosensitizer, which inhibits the radiation-induced phosphorylation of epidermal growth factor receptor (EGFR) and the downstream pathway, and therefore enhances radiosensitivity in cholangiocarcinoma cells [1,2]. Here, EGFR is linked to cholangiocarcinoma.